Please note: This website includes an accessibility system. Press Control-F11 to adjust the website to the visually impaired who are using a screen reader; Press Control-F10 to open an accessibility menu.

by

Homepage
Tags search
Pharmaceuticals

CTech 24/7

More stories in CTech

Pharmaceuticals

102 stories about Pharmaceuticals

Teva signals return to fundraising after decade-long crisis
08.02.25|Sophie ShulmanIsraeli pharmaceutical giant eyes stock offering as part of its recovery plan.
Teva’s stock surge comes to a halt, falling 14% amid weak 2025 outlook
30.01.25|Sophie ShulmanDespite a strong 80% gain in 2024, Teva’s stock dropped after the company revealed disappointing profitability and cash flow forecasts.
Teva’s 10-year turnaround takes shape with stunning trial results
18.12.24|Sophie ShulmanDuvakitug signals a brighter future for the Israeli pharma giant.
Teva shares jump as its most promising drug shows exceptional trial results
17.12.24|Sophie ShulmanDuvakitug, designed to treat colitis and Crohn’s disease, exceeded expectations and positions Teva to compete in the $28 billion global market for inflammatory bowel disease treatments.
Teva's vision 2025: Building on momentum for future market leadership
04.08.24|Sophie ShulmanRichard Francis’ strategic plan aims to transform Teva into a powerhouse of growth and innovation.
Teva posts impressive Q2 results, ups 2024 revenue forecast
31.07.24|Sophie ShulmanStrong sales of Austedo and Ajovy lead to double-digit growth for the Israeli pharma company.
Cyber attack shuts down Israeli pharma company's distribution
17.06.24|Omer KabirRekah, a prominent local producer of medicines, cosmetics, vitamins, and nutritional supplements, said it is working "to contain the incident, locate and thwart it, and restore compromised systems to operation"
Teva shares continue to surge, climb to highest mark in more than five years on Q1 results
08.05.24|Sophie ShulmanAUSTEDO continues to be Teva's main growth engine and its flagship drug, with annual growth of 67% in sales
Why are Teva shares surging and how does it plan to keep it up
04.04.24|Uri Tel TenneSince the beginning of the year, Teva's shares have risen by about 36%, and are among the best performing stocks on the Tel Aviv Stock Exchange. Why is this happening and how is the company's CEO planning to build on the momentum?
"Until there is unity and equality here, Israel has no chance"
22.02.24|Sophie ShulmanAt night, serial entrepreneur Michal Tsur doesn’t sleep, worrying about her son fighting in the army. During the day, she is busy with her third startup, Remepy, and dreaming of a new country - the same country for which she took to the streets as one of the leaders of last year’s protest against the judicial reform
Teva CEO: "The company played not to lose, now we’ll play to win"
21.02.24|Sophie ShulmanRichard Francis' decision to focus on innovative drugs has boosted the stock by 40% since he took office. However, the high debt is still burdensome and the realization of the potential depends on the success of developments that are still in the laboratory
Teva CEO: Israel’s production capacity has not been affected by the war
08.11.23|Sophie ShulmanThe Israeli pharmaceutical company’s revenues grew by 7% in the last quarter to $3.9 billion, according to a report it recently published.
The Israeli startup using spatial biology to provide better cancer treatment
02.01.22|Yafit OvadiaNucleai is looking at the way cells interplay and are interspersed within human tissue to develop precision medicine solutions
CytoReason enters Japanese market with SPI partnership
30.09.21|James SpiroThis is the first time that collaboration between an Israeli company and a Japanese pharmaceutical company has been announced to bring AI to clinical drug development
Israel’s RedHill Biopharma testing oral pill that cures Covid-19 symptoms
28.02.21|Yafit OvadiaIsraeli pharmaceutical company creates treatment to help severe and moderately-ill patients; company generates $90 million in sales annually
Due to high demand for biotech, Pontifax crosses $1.3 billion funding threshold
12.10.20|Tzally GreenbergA series of successful exits and investments see the Israeli fund balloon by 22% to hit $404 million since the start of the Covid-19 crisis
What’s behind the timed resurgence of lawsuits against Teva?
28.08.20|Sophie ShulmanThe Israeli pharmaceutical giant was hit with three legal blows over the course of a few days
Hitting the Reset Button on Antibiotics
17.04.20|Viki AuslenderAs the world faces the global threat of Covid-19 and the post antibiotic era, MIT researcher Regina Barzilay and her team are using AI to discover new chemical compounds for medical treatment
Pharmaceutical Company AstraZeneca Launches Digital Health Program in Israel
27.11.19|Meir OrbachAlongside funding, the program will provide Israeli startups with mentorship and training
Teva Quarterly Report Meets Analyst Expectations
07.11.19|Sophie Shulman The Israeli drugmaker’s revenues dropped 6% in the third quarter of 2019 to $4.26 billion. Debt dropped by $1.8 billion to $26.9 billion

About CTech Terms of Use Privacy Policy

Back to Top